Antonio Galvano

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Francesco Passiglia, Giuseppe Bronte, Viviana Bazan et al. · Oncotarget · 2016 · 165 citations · Full text

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina et al. · Advances in Therapy · 2020 · 165 citations

Medicine, Immunology, Hematology +9

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

Francesco Passiglia, Antonio Galvano, Marta Castiglia et al. · Therapeutic Advances in Medical Oncology · 2019 · 64 citations · Full text

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score

Antonio Galvano, Marta Peri, Aurelia Guarini et al. · Therapeutic Advances in Medical Oncology · 2020 · 58 citations · Full text